EC Number |
Recommended Name |
Source Tissue |
Reference |
---|
1.1.1.1 | alcohol dehydrogenase |
blood serum |
among all tested classes of ADH isoenzymes, only class I has higher activity in serum of patients with breast cancer in stage IV. The total ADH activity is not significantly higher in patients with breast cancer than in healthy controls. The changes in activity, especially in class I ADH, appear to be caused by isoenzymes being released from the organ damaged by metastatic disease |
669630 |
1.1.1.1 | alcohol dehydrogenase |
blood serum |
the total ADH activity is significantly higher (44%) among patients with cancer than healthy ones. The activity of class I ADH isoenzymes is elevated only in the serum of patients with metastatic liver cancer. This increase of activity seems to be caused by the enzyme released from liver cancer cells and primary tumors originating in other organs |
687976 |
1.1.1.27 | L-lactate dehydrogenase |
blood serum |
the level of L-lactate dehydrogenase B are specifically increased in non-small cell lung cancer |
670115 |
1.1.1.28 | D-lactate dehydrogenase |
blood serum |
- |
-, 740891 |
1.10.3.3 | L-ascorbate oxidase |
blood serum |
- |
765849 |
1.11.1.6 | catalase |
blood serum |
catalase activity is significantly higher in patients with renal cell carcinoma than in controls |
758318 |
1.11.1.9 | glutathione peroxidase |
blood serum |
- |
764515 |
1.14.11.4 | procollagen-lysine 5-dioxygenase |
blood serum |
- |
722865 |
1.14.17.1 | dopamine beta-monooxygenase |
blood serum |
- |
438631, 438632, 703268 |
1.14.17.1 | dopamine beta-monooxygenase |
blood serum |
activity is highest in 5-day-old rats, it decreases till the age of 14 days and increases mainly in 14-day to 35-day-old animals, significant decrease in activity in rats between 35 to 40 days, adult rats aged 90-120 days show a stable activity of dopamine bet-hydroxylase |
660083 |
1.14.17.1 | dopamine beta-monooxygenase |
blood serum |
enzyme activity in children and adolescents increases with the age between 3-10 years, later it decreases approximately by the age of 10-14 years. At the age of 21 to 60 years the dopamine-beta-hydroxylase level is stable |
660083 |
1.14.19.3 | acyl-CoA 6-desaturase |
blood serum |
- |
745488 |
1.14.19.30 | acyl-lipid (8-3)-desaturase |
blood serum |
- |
745488, 745593 |
1.16.3.1 | ferroxidase |
blood serum |
- |
-, 744016, 744470 |
1.4.3.21 | primary-amine oxidase |
blood serum |
decreased SSAO serum activity in schizophrenic patients treated with second generation antipsychotics known to disturb glucose metabolism |
686502 |
1.4.3.21 | primary-amine oxidase |
blood serum |
reduced enzyme activity is found in haemodialysed uremic patients before and after dialysis treatment, compared to controls. The activity is slightly lower in peritoneally dialysed, and normal in not dialysed patients. In haemodialysed patients SSAO activity is elevated compared to controls |
688488 |
1.4.3.21 | primary-amine oxidase |
blood serum |
treatment with benzylamine + vanadate reduces the elevated serum SSAO activity, decreases the accumulation of advanced-glycation end products and increases the bioavailability of nitric oxide in diabetic animals, similarly to insulin |
688489 |
1.4.3.22 | diamine oxidase |
blood serum |
- |
686654, 701603 |
1.4.3.22 | diamine oxidase |
blood serum |
a significantly lower serum diamine oxidase is found in the pseudoallergy group compared with the allergy group |
763860 |
1.4.3.22 | diamine oxidase |
blood serum |
mean/median concentrations are between 0.5 and 1.5 ng/ml in healthy volunteers (n=58) and mastocytosis patients (n=19) and plateau at approximately 145 ng/ml during pregnancy |
764513 |
1.4.3.22 | diamine oxidase |
blood serum |
the mean activity is 7.59 U/l for women and 2.38 U/l for men. Gender is a major determinant for DAO activity in healthy subjects |
686129 |
1.4.3.22 | diamine oxidase |
blood serum |
variant ABP1 alleles leading to the amino-acid substitutions Thr16Met, Ser332Phe and His645Asp are identified with frequencies of 25.4, 6.3 and 30.6%, respectively. Over 70% of the population carry at least one amino-acid substitution. Individuals carrying the 645Asp amino acid display lower serum diamine oxidase activity as compared with noncarriers with a significant gene-dose effect. This is due to an increase in the Michaelis-Menten constant. Individuals heterozygous for 645Asp show Vmax/Km values of 66% and homozygous 51% as compared with noncarriers. The effect of the 16Met variant allele is lower and that of the rarest allele 332Phe is negligible |
689356 |
1.4.3.3 | D-amino-acid oxidase |
blood serum |
- |
763710 |
1.4.3.4 | monoamine oxidase |
blood serum |
no significant gender-related difference in SSAO activity |
689723 |
1.4.4.2 | glycine dehydrogenase (aminomethyl-transferring) |
blood serum |
- |
763473 |
2.1.1.5 | betaine-homocysteine S-methyltransferase |
blood serum |
- |
733463, 733673 |
2.1.3.3 | ornithine carbamoyltransferase |
blood serum |
- |
756979 |
2.3.2.13 | protein-glutamine gamma-glutamyltransferase |
blood serum |
enhanced serum immunoreactivity to tTG-2 antigens in some patients with multiple myeloma |
685824 |
2.3.2.2 | gamma-glutamyltransferase |
blood serum |
- |
684743, 684787, 686110, 686301, 687153 |
2.3.2.2 | gamma-glutamyltransferase |
blood serum |
association between serum gamma-glutamyltransferase and type 2 diabetes |
686319 |
2.3.2.2 | gamma-glutamyltransferase |
blood serum |
association between serum gamma-glutamyltransferase levels and coronary microvascular function in hypertensive patients |
688145 |
2.3.2.2 | gamma-glutamyltransferase |
blood serum |
associations of gamma-glutamyltransferase with fasting glucose and HbA1c are stronger in women with diabetes compared to women without diabetes. gamma-Gutamyltransferase is associated with fasting insulin to the same extent in all women, irrespective of diabetes status. Results excluding hyperinsulinemic women, i.e., in the highest fourth of the fasting insulin distribution, are similar to those obtained for all non-diabetic women as are results excluding women in the highest quartile of the alcohol consumption distribution and for women with alanine aminotransferase and gamma-glutamyltransferase levels within the normal range |
687004 |
2.3.2.2 | gamma-glutamyltransferase |
blood serum |
elevated gamma-glutamyltransferase is associated with significantly increased risk of stroke, fatal coronary heart disease events and cardiovascular disease mortality independent of established cardiovascular disease risk factors and may be a useful additional marker for long-term cardiovascular disease |
695962 |
2.3.2.2 | gamma-glutamyltransferase |
blood serum |
gamma-glutamyltransferase can be used as a marker related with oxidative stress |
687000 |
2.3.2.2 | gamma-glutamyltransferase |
blood serum |
gamma-glutamyltransferase is associated with mortality in both men and women, especially in patients younger than 30 years. Even high-normal gamma-glutamyltransferase is a risk factor for all-cause mortality |
686321 |
2.3.2.2 | gamma-glutamyltransferase |
blood serum |
gamma-glutamyltransferase is independently associated with an increased level of C-reactive protein in both males and females. In addition, in males, gamma-glutamyltransferase is related to an increased level of arterial stiffness |
689280 |
2.3.2.2 | gamma-glutamyltransferase |
blood serum |
gamma-glutamyltransferase level is related to adiponectin level in nonalcoholic women without liver disease |
688817 |
2.3.2.2 | gamma-glutamyltransferase |
blood serum |
GGT activities from 1147 moderate drinkers and 449 abstainers are classified according to body mass index are compared with those of 208 heavy drinkers admitted for detoxification. GGT upper normal limits, defined based on normal weight abstainers are lower than those based on moderate drinkers. The relative increases in GGT activities in male moderate drinkers with overweight (54%) or obesity (125%) exceedes the corresponding changes found in women (25% and 75%, respectively). The BMI-dependent variation on the sensitivity of GGT for correctly classifying heavy drinkers ranges from 29% to 67%. The rates of false-positive values in the subgroups from low to high BMI varies from 0% to 27%, respectively |
690044 |
2.3.2.2 | gamma-glutamyltransferase |
blood serum |
GGT is closely related with insulin resistance and the increased number of components of metabolic syndrome. Among components of metabolic syndrome, serum GGT may be more associated with dyslipidemia and abnormal glucose tolerance, suggesting that serum GGT has more relationship with hepatic insulin resistance regardless of non-alcoholic fatty liver disease |
686311 |
2.3.2.2 | gamma-glutamyltransferase |
blood serum |
GGT level has positive correlation with family history of liver disease |
677259 |
2.3.2.2 | gamma-glutamyltransferase |
blood serum |
GGT levels are increased significantly in Alzheimers disease patients |
687197 |
2.3.2.2 | gamma-glutamyltransferase |
blood serum |
GSTM1- and GSTM1-/GSTT1- genotypes may be a genetic risk factor for the increase of GGT in Japanese epileptic patients treated with valproic acid patients. It is not possible to clarify whether the GGT increase is caused by valproic acid-induced hepatotoxicity or not |
686165 |
2.3.2.2 | gamma-glutamyltransferase |
blood serum |
habitual coffee consumption is associated with lower incidence of type II diabetes particularly in those with higher baseline serum GGT levels |
686500 |
2.3.2.2 | gamma-glutamyltransferase |
blood serum |
high serum gamma-glutamyltransferase is associated with an increased risk of liver cancer |
687012 |
2.3.2.2 | gamma-glutamyltransferase |
blood serum |
higher serum gamma-glutamyltransferase levels are associated with prehypertension in a nationally representative sample of US adults, free of cardiovascular disease and hypertension |
686109 |
2.3.2.2 | gamma-glutamyltransferase |
blood serum |
higher serum gamma-glutamyltransferase levels are independently associated with impaired coronary microvascular function in patients with dilated cardiomyopathy |
684806 |
2.3.2.2 | gamma-glutamyltransferase |
blood serum |
increased GGT activities are independently associated with a more atherogenic lipid profile in general population |
686163 |
2.3.2.2 | gamma-glutamyltransferase |
blood serum |
presence in plaques of a serum-like gamma-glutamyltransferase protein, indicating that a direct contribution of serum gamma-glutamyltransferase to enzyme activity found within atherosclerotic lesions is possible. Occurrence of gamma-glutamyltransferase-mediated redox reactions within plaque environment might influence plaque progression |
684807 |
2.3.2.2 | gamma-glutamyltransferase |
blood serum |
serum gamma-glutamyltransferase levels are positively associated with peripheral arterial disease among men (peripheral arterial disease) but not women |
684804 |
2.3.2.2 | gamma-glutamyltransferase |
blood serum |
serum GGT activity is increased in patients with calcific aortic stenosis. These increases seem to occur in advanced rather than milder forms of calcific aortic valve disease |
688133 |
2.3.2.2 | gamma-glutamyltransferase |
blood serum |
serum GGT is specifically associated with the visceral fat area, but not with the subcutaneous fat area, suggests that the serum GGT may be useful as a convenient indicator of visceral fat area in the clinical treatment of obesity |
686312 |
2.3.2.2 | gamma-glutamyltransferase |
blood serum |
serum GGT within its normal range can predict cardiovascular diseases mortality in those aged less than 70 years, but may have limited usefulness for risk assessment in older adults |
686498 |
2.3.2.2 | gamma-glutamyltransferase |
blood serum |
strong interaction between serum gamma-glutamyltransferase and obesity on the risk of prevalent type 2 diabetes |
686146 |
2.3.2.2 | gamma-glutamyltransferase |
blood serum |
subjects are divided into four groups according to their level of alcohol consumption: nondrinkers, light drinkers (1-188 ml/week), intermediate drinkers (189-377 ml/week), and heavy drinkers (more than 378 ml/week). The frequency of subjects with an fasting plasma glucose of 110 mg/dl or more rises significantly as alcohol consumption increases, from 6.7% in non-drinkers to 10.1% in intermediate drinkers and 12.1% in heavy drinkers. When only the subjects with a gamma-glutamyltransferase level of less than 40 IU/l are analyzed, no difference is observed in the frequency of subjects with an FPG level of 110 mg/dl or more among the four groups |
686313 |
2.4.1.22 | lactose synthase |
blood serum |
- |
488944, 488947 |
2.4.1.225 | N-acetylglucosaminyl-proteoglycan 4-beta-glucuronosyltransferase |
blood serum |
- |
488953 |
2.4.1.226 | N-acetylgalactosaminyl-proteoglycan 3-beta-glucuronosyltransferase |
blood serum |
- |
488967 |
2.4.1.226 | N-acetylgalactosaminyl-proteoglycan 3-beta-glucuronosyltransferase |
blood serum |
fetal bovine serum |
488968 |
2.4.1.69 | type 1 galactoside alpha-(1,2)-fucosyltransferase |
blood serum |
- |
489350, 489352 |
2.4.1.69 | type 1 galactoside alpha-(1,2)-fucosyltransferase |
blood serum |
from AB and mixed secretor phenotype individuals |
489349 |
2.4.1.69 | type 1 galactoside alpha-(1,2)-fucosyltransferase |
blood serum |
of donors of all ABO blood-groups examined, except those of the rare Oh (Bombay) and Bh phenotypes |
489348 |
2.4.2.12 | nicotinamide phosphoribosyltransferase |
blood serum |
similar mRNA expression levels in (fa/fa) Zucker rats (obese) compared to lean Zucker rats (control) as well as in cafeteria diet-fed Wistar rats (diet-induced obesity) compared to standard chow diet-fed Wistar rats (control) |
692570 |
2.4.2.26 | protein xylosyltransferase |
blood serum |
elevated xylosyltransferase I activities in Pseudoxanthoma elasticum patients |
681502 |
2.4.2.26 | protein xylosyltransferase |
blood serum |
increased activity of xylosyltransferase I in the blood serum of patients with connective tissue diseases |
679274 |
2.4.2.26 | protein xylosyltransferase |
blood serum |
patients with osteoarthritis |
657789 |
2.4.2.26 | protein xylosyltransferase |
blood serum |
XylT2 is predominant |
703904 |
2.4.2.26 | protein xylosyltransferase |
blood serum |
XylT2 is predominant. XylT levels in serum are approximately 200% higher than those in plasma due in part to XylT released by platelets during blood clotting in vitro. In Xylt2+/+ mice, total serum XylT activity is 42% higher than in plasma. In Xylt2-/- mice, no significant difference between serum and plasma total XylT activity |
703904 |
2.4.2.4 | thymidine phosphorylase |
blood serum |
presurgery serum from 47 patients with ovarian cancer, and control serum from women with normal ovaries, treated surgically due to nononcological reasons. Significant higher enzyme activity in malignant serum specimen from ovarian cancer patients when compared to the control |
658872 |
2.4.3.1 | beta-galactoside alpha-(2,6)-sialyltransferase |
blood serum |
level of serum ST6Gal I in patients with chronic active hepatitis is significantly increased compared to that in patients with chronic persistent hepatitis. Serum level of ST6Gal I in hepatitis C patients is correlated with the activity of hepatic inflammation, but not with liver fibrosis |
703898 |
2.6.1.2 | alanine transaminase |
blood serum |
- |
721277 |
2.7.1.171 | protein-fructosamine 3-kinase |
blood serum |
- |
738074 |
2.7.1.21 | thymidine kinase |
blood serum |
- |
671360, 750551 |
2.7.2.3 | phosphoglycerate kinase |
blood serum |
of 10 cancer patients whose serum is tested, 3 of 4 with pancreatic cancer have 65-900% higher levels of PGK1 than that found in normal serum |
688148 |
2.7.3.2 | creatine kinase |
blood serum |
- |
721916 |
2.7.3.2 | creatine kinase |
blood serum |
phenylbutyrate greatly decreases the adriamycin-associated elevations of serum lactate dehydrogenase and creatine kinase activities, two nonspecific widely used cardiac injury markers |
686860 |
3.1.1.111 | phosphatidylserine sn-1 acylhydrolase |
blood serum |
- |
753301, 753940 |
3.1.1.2 | arylesterase |
blood serum |
- |
35213, 35215, 646527, 650953, 664184, 665960, 666183, 677892, 679182, 679306, 749610, 749628, 750345, 750428, 750482, 750483, 750511, 750758, 752150, 752173 |
3.1.1.2 | arylesterase |
blood serum |
contains A-type paraoxonase and B-type paraoxonase |
646527 |
3.1.1.2 | arylesterase |
blood serum |
enzyme activity against the phenylacetate is higher, and phenotype-dependent, only in diabetic patients with type II diabetes mellitus. Less antiatherogenic paraoxonase B allele is more frequent in type II diabetes mellitus than in the healthy population. Their lipid status is more atherogenic, which could indicate a risk of premature atherosclerosis |
677411 |
3.1.1.2 | arylesterase |
blood serum |
in serum, the esterase is tightly bound to the high density lipoproteins, particularly apo A-l |
646509 |
3.1.1.2 | arylesterase |
blood serum |
in the blood of Gulf War veterans who developed delayed neurotoxicity symptoms the levels of serum paraoxonase (PON1) isozyme type Q is significantly lower than in the control, unaffected veteran group |
646528 |
3.1.1.2 | arylesterase |
blood serum |
of A and B phenotypes. Human serum contains a single enzyme with both paraoxonase and arylesterase activities |
35212 |
3.1.1.2 | arylesterase |
blood serum |
phenylketonuric patients. Paraoxonase/arylesterase activities are strongly related to the dietary control of phenylketonuric patients |
679634 |
3.1.1.2 | arylesterase |
blood serum |
PON1 activity determined towards the synthetic compounds paraoxon and phenyl acetate reflects no association with markers of oxidative stress |
677297 |
3.1.1.25 | 1,4-lactonase |
blood serum |
- |
650953, 665960, 681264, 749628, 750345, 750428, 750462, 750511, 751389 |
3.1.1.47 | 1-alkyl-2-acetylglycerophosphocholine esterase |
blood serum |
- |
-, 690429, 694940, 716432 |
3.1.1.47 | 1-alkyl-2-acetylglycerophosphocholine esterase |
blood serum |
no statistical differences in PAF-AH activity between serologically negative horses, with 740 U/l, and those with residual, 735 U/l, and high antibody titre on leptospirosis, 790 U/l, respectively |
713682 |
3.1.1.56 | methylumbelliferyl-acetate deacetylase |
blood serum |
autoantibodies detectable in patients with Behcets disease (BD, 25%), Vogt-Koyanagi-Harada disease (VKH, 25%), and sarcoidosis (17.6%) |
700318 |
3.1.1.56 | methylumbelliferyl-acetate deacetylase |
blood serum |
IgG1 autoantibodies detected in mice with experimental autoimmune uveoretinitis |
700318 |
3.1.1.7 | acetylcholinesterase |
blood serum |
activity increases in serum of animal intoxicated by aflatoxins (group B) |
757608 |
3.1.1.8 | cholinesterase |
blood serum |
- |
678541, 691094, 691944, 693402 |
3.1.1.8 | cholinesterase |
blood serum |
the low concentration of BoBChE in serum is explained by limited quantities of an unidentified polyproline-rich protein |
750289 |
3.1.4.39 | alkylglycerophosphoethanolamine phosphodiesterase |
blood serum |
- |
679257, 680318 |
3.1.4.39 | alkylglycerophosphoethanolamine phosphodiesterase |
blood serum |
activity progressively increases throughout pregnancy |
700238 |
3.1.4.50 | glycosylphosphatidylinositol phospholipase D |
blood serum |
- |
666244, 668244, 669623 |
3.1.4.50 | glycosylphosphatidylinositol phospholipase D |
blood serum |
no acitivity in blood serum |
682945 |
3.1.8.1 | aryldialkylphosphatase |
blood serum |
- |
35192, 35208, 35213, 35215, 646527, 650953, 664184, 665960, 666183, 677892, 679182, 679306, 681264, 749628, 750345, 750428, 750482, 750483, 750511, 752150, 752173 |
3.1.8.1 | aryldialkylphosphatase |
blood serum |
contains A-type paraoxonase and B-type paraoxonase |
646527 |
3.1.8.1 | aryldialkylphosphatase |
blood serum |
determination of the distribution of the PON1 192Q/R and -108C/T polymorphisms in a Peruvian population and comparison of the distribution of these polymorphisms with those of other world populations |
679530 |
3.1.8.1 | aryldialkylphosphatase |
blood serum |
in serum, the esterase is tightly bound to the high density lipoproteins, particularly apo A-l |
646509 |